Item 1. Security and Issuer.
This Amendment No. 7 (“Amendment No. 7”) to Schedule 13D amends the statement on Schedule 13D filed on July 31, 2017 (the
“Original Schedule 13D”), as amended on January 23, 2019, July 30, 2020, September 21, 2021, February 15, 2022, November 20, 2023 and April 29, 2024 (the “Prior Amendments”, and together with the
Original Schedule 13D and this Amendment No. 7, the “Schedule 13D”) with respect to the Common Stock of Alpine Immune Sciences, Inc (the “Issuer”), having its principal executive office at 188 East Blaine St., Suite 200,
Seattle, WA 98102. Except as otherwise specified in Amendment No. 7, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 7 and not otherwise defined
herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.
Item 3. Source and Amount of
Funds or Other Consideration
FLS-VIII purchased from a company then known as Alpine Immune Sciences, Inc.
(“Old Alpine”) in a series of private transactions 3,558,719 shares of Series A-1 Preferred Stock (“Series A-1 Stock”) and 866,741
shares of Common Stock (the “Old Alpine Common Stock”) for an aggregate purchase price of $15,483,870. Pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017, by and among the
Issuer, Nautilus Merger Sub, Inc. and Old Alpine (the “Merger Agreement”), at the closing of the merger provided for in the Merger Agreement (the “Merger”), each share of Old Alpine’s Common Stock and Series A-1 Stock held by FLS-VIII was automatically converted into 0.4969 shares of the Issuer’s Common Stock, which resulted in FLS-VIII
holding a total of 2,199,011 shares of the Issuer’s Common Stock as of July 24, 2017.
On January 18, 2019,
FLS-VIII participated in the Issuer’s private placement offering and (i) purchased 372,439 shares of the Issuer’s Common Stock and (ii) received a warrant exercisable for 145,251 shares of
the Issuer’s Common Stock for an aggregate purchase price of $1,999,997.
On September 17, 2021,
FLS-VIII exchanged 1,200,000 shares of the Issuer’s Common Stock for a warrant to purchase 1,200,000 shares of the Issuer’s Common Stock.
On February 11, 2022, FLS-VIII purchased 112,665 shares of the Issuer’s Common Stock for an aggregate
purchase price of $799,990.
On December 11, 2023, FLS-VIII exercised the warrant for 145,251 shares of the
Issuer’s Common Stock.
On April 25, 2024, FLS-VIII cashless exercised the warrant for 1,200,000 shares
of the Issuer’s Common Stock, which resulted in the Issuer withholding 19 shares of Common Stock to pay the exercise price and issuing FLS-VIII the remaining 1,199,981 shares of Common Stock.
On September 15, 2021, FLSPF purchased 394 shares of the Issuer’s Common Stock for an aggregate purchase price of $3,704.
On September 17, 2021, FLSPF participated in the Issuer’s private placement offering (the “Offering”) pursuant to which it purchased a pre-funded warrant for 1,702,127 shares of the Issuer’s Common Stock for an aggregate purchase price of $15,999,994. FLSPF also purchased 400,000 shares of the Issuer’s Common Stock from another
stockholder of the Issuer for a total purchase price of $3,760,000.
On February 11, 2022, FLSPF purchased 1,088,179 shares of the Issuer’s
Common Stock for an aggregate purchase price of $7,726,724.